Change in use of topical active treatment ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Change from baseline in disease severity according to participants ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Participant satisfaction · people with eczema
1 finding from 1 review
Number of participants reporting an adverse event · people with eczema
It is very uncertain whether topical active treatment in combination with moisturiser changes number of participants reporting an adverse event compared with topical active treatment alone (very low certainty).
1 finding from 1 review
Change from baseline in disease severity as assessed by the investigators · people with eczema
1 finding from 1 review
Number of participants who experienced a flare · people with eczema
Topical active treatment in combination with moisturiser may leads to lower number of participants who experienced a flare compared with topical active treatment alone (low certainty).
1 finding from 1 review
Change from baseline in health‐related quality of life · people with eczema
1 finding from 1 review
Intervention not reported
Primary outcome 1: participant‐ or parent‐rated symptoms of eczema (SCORAD part C) at the end of active treatment Visual analogue scale for itch and sleep disturbance ranging from 0 to 10 for each symptom and combined ranging from 0 to 20. The hig... · male and female patients 0 to 55 years of age with physician‐diagnosed eczema
1 finding from 1 review
Intervention not reported
Primary outcome 1: participant‐ or parent‐rated global change in eczema symptoms at the end of active treatment (binary outcome) Change in risk for worsened/unchanged eczema Duration of · male and female patients 0 to 55 years of age with physician‐diagnosed eczema
The intervention showed no clear difference in primary outcome 1: participant‐ or parent‐rated global change in… (low certainty).
1 finding from 1 review
Intervention not reported
Primary outcome 2: participant‐ or parent‐rated participant quality of life score at the end of active treatment Scales used: DLQI, IDQoL, Skindex‐29, CDLQI. On those scales, the higher the score, the more severely the quality of life is affected ... · male and female patients 0 to 55 years of age with physician‐diagnosed eczema
1 finding from 1 review
Intervention not reported
Primary outcome 2: participant‐ or parent‐rated family quality of life score at the end of active treatment Scale used: DFI, FDLQI. On those scales, the higher the score, the more severely the quality of life is affected Duration of · male and female patients 0 to 55 years of age with physician‐diagnosed eczema
1 finding from 1 review
Intervention not reported
Secondary outcome 4: global eczema severity score (total SCORAD) at the end of active treatment (Investigator‐rated eczema severity) Scale used: total SCORAD ranging from 0 to 103. The higher the score, the more severe the disease Duration of · male and female patients 0 to 55 years of age with physician‐diagnosed eczema
1 finding from 1 review
Intervention not reported
Secondary outcome 6: adverse events (gastrointestinal symptoms) during active treatment Duration of · male and female patients 0 to 55 years of age with physician‐diagnosed eczema
The intervention showed no clear difference in secondary outcome 6: adverse events (gastrointestinal symptoms)… (low certainty).
1 finding from 1 review
Change in use of topical active treatment ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Change in use of topical active treatment ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Change in use of topical active treatment ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Change in use of topical active treatment ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Change in use of topical active treatment ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
Oral methotrexate and oral prednisone may leads to higher primary outcome: Global improvement of disease activity or damage… compared with placebo and oral prednisone (low certainty).
1 finding from 1 review
Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
Narrowband UVB phototherapy may leads to lower primary outcome: Adverse effects compared with medium‐dose UVA‐1 phototherapy (50 J/cm²) (low certainty).
1 finding from 1 review